{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:18:58Z","timestamp":1793128738996,"version":"4.5.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-021-03908-x","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:03:17Z","timestamp":1643241797000},"page":"1111-1124","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage"],"prefix":"10.1007","volume":"40","author":[{"given":"Adithya","family":"Balasubramanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashray","family":"Gunjur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Weickhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Bolton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1138-6389","authenticated-orcid":false,"given":"Marlon","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"3908_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.10.008","author":"GB Schulz","year":"2019","unstructured":"Schulz GB, Grimm T, Buchner A, Jokisch F, Kretschmer A, Stief CG et al (2019) Bladder Cancer Stage Development, 2004\u20132014 in Europe Compared With the United States: Analysis of European Population-based Cancer Registries, the United States SEER Database, and a Large Tertiary Institutional Cohort. Clin Genitourin Cancer. https:\/\/doi.org\/10.1016\/j.clgc.2019.10.008","journal-title":"Clin Genitourin Cancer"},{"key":"3908_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/MOU.0000000000000078","volume":"24","author":"M Mossanen","year":"2014","unstructured":"Mossanen M, Gore JL (2014) The burden of bladder cancer care: direct and indirect costs. Curr Opin Urol 24:487\u2013491","journal-title":"Curr Opin Urol"},{"key":"3908_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","volume":"72","author":"V Soukup","year":"2017","unstructured":"Soukup V, \u010capoun O, Cohen D, Hern\u00e1ndez V, Babjuk M, Burger M et al (2017) Prognostic performance and reproducibility of the 1973 and 2004\/2016 World Health Organization grading classification systems in non\u2013muscle-invasive bladder cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Syst. Eur Urol 72:801\u2013813","journal-title":"Eur Urol"},{"key":"3908_CR4","doi-asserted-by":"publisher","first-page":"e651","DOI":"10.1016\/j.clgc.2020.03.013","volume":"18","author":"KH Tully","year":"2020","unstructured":"Tully KH, Roghmann F, Noldus J, Chen X, H\u00e4user L, Kibel AS et al (2020) Quantifying the overall survival benefit with early radical cystectomy for patients with histologically confirmed t1 non\u2013muscle-invasive bladder cancer. Clin Genitourin Cancer 18:e651\u2013e659","journal-title":"Clin Genitourin Cancer"},{"key":"3908_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14065","author":"M Perera","year":"2017","unstructured":"Perera M, Papa N, Christidis D, McGrath S, Manning T, Roberts M et al (2017) The impact of the global BCG shortage on treatment patterns: population-based data. BJU Int. https:\/\/doi.org\/10.1111\/bju.14065","journal-title":"BJU Int"},{"key":"3908_CR6","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"M-O Grimm","year":"2020","unstructured":"Grimm M-O, van der Heijden AG, Colombel M, Muilwijk T, Mart\u00ednez-Pi\u00f1eiro L, Babjuk MM et al (2020) Treatment of high-grade non\u2013muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial \u201cNIMBUS.\u201d Eur Urol 78:690\u2013698","journal-title":"Eur Urol"},{"key":"3908_CR7","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","volume":"196","author":"SS Chang","year":"2016","unstructured":"Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. J Urol 196:1021\u20131029","journal-title":"J Urol"},{"key":"3908_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JGO.19.11000","volume":"5","author":"ML Wroclawski","year":"2019","unstructured":"Wroclawski ML, Schutz FA, Cha JD, Soares A (2019) Alternative therapies to Bacillus Calmette-Gu\u00e9rin shortage for nonmuscle invasive bladder cancer in Brazil and other underdeveloped countries: management considerations. J Glob Oncol 5:1\u20139","journal-title":"J Glob Oncol"},{"key":"3908_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5152\/tud.2014.94715","volume":"40","author":"M Jurewicz","year":"2014","unstructured":"Jurewicz M, Soloway MS (2014) Approaching the optimal transurethral resection of a bladder tumor. Turk J Urol 40:73\u201377","journal-title":"Turk J Urol"},{"key":"3908_CR10","first-page":"40","volume":"25","author":"F Bray","year":"2016","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. Eur Urol 25:40\u201348","journal-title":"Eur Urol"},{"key":"3908_CR11","unstructured":"National Collaborating Centre for Cancer (UK) (2015) Bladder cancer: diagnosis and management. National Institute for Health and Care Excellence (UK), London"},{"key":"3908_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, B\u00f6hle A, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447\u2013461","journal-title":"Eur Urol"},{"key":"3908_CR13","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/j.1464-410X.2008.07966.x","volume":"102","author":"HW Herr","year":"2008","unstructured":"Herr HW, Donat SM (2008) Quality control in transurethral resection of bladder tumours. BJU Int 102:1242\u20131246","journal-title":"BJU Int"},{"key":"3908_CR14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.eururo.2009.05.047","volume":"57","author":"P Mariappan","year":"2010","unstructured":"Mariappan P, Zachou A, Grigor KM (2010) Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 57:843\u2013849","journal-title":"Eur Urol"},{"key":"3908_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1464-410X.2012.11619.x","volume":"110","author":"C Logan","year":"2012","unstructured":"Logan C, Brown M, Hayne D (2012) Intravesical therapies for bladder cancer\u2014indications and limitations. BJU Int 110:12\u201321","journal-title":"BJU Int"},{"key":"3908_CR16","doi-asserted-by":"publisher","unstructured":"(1994) The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer. Br J Urol 73(6):632\u2013638. https:\/\/doi.org\/10.1111\/j.1464-410x.1994.tb07547.x","DOI":"10.1111\/j.1464-410x.1994.tb07547.x"},{"key":"3908_CR17","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","volume":"55","author":"S Gudj\u00f3nsson","year":"2009","unstructured":"Gudj\u00f3nsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T et al (2009) Should all patients with non\u2013muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 55:773\u2013780","journal-title":"Eur Urol"},{"key":"3908_CR18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00345-011-0691-2","volume":"29","author":"C De Nunzio","year":"2011","unstructured":"De Nunzio C, Carbone A, Albisinni S, Alpi G, Cantiani A, Liberti M et al (2011) Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial. World J Urol 29:517\u2013521","journal-title":"World J Urol"},{"key":"3908_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"RJ Sylvester","year":"2016","unstructured":"Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S et al (2016) Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa\u2013pT1 Urothelial Ca. Eur Urol 69:231\u2013244","journal-title":"Eur Urol"},{"key":"3908_CR20","first-page":"179918","volume":"37","author":"AA Elsawy","year":"2019","unstructured":"Elsawy AA, El-Assmy AM, Bazeed MA, Ali-El-Dein B (2019) The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non\u2013muscle-invasive bladder cancer: a preliminary results of randomized controlled trial. Urol Oncol Semin Orig Invest 37:179918","journal-title":"Urol Oncol Semin Orig Invest"},{"key":"3908_CR21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.eururo.2017.06.038","volume":"73","author":"J Bosschieter","year":"2018","unstructured":"Bosschieter J, Nieuwenhuijzen JA, van Ginkel T, Vis AN, Witte B, Newling D et al (2018) Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients. Eur Urol 73:226\u2013232","journal-title":"Eur Urol"},{"key":"3908_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/bju.14124","volume":"122","author":"J Bosschieter","year":"2018","unstructured":"Bosschieter J, van Moorselaar RJA, Vis AN, van Ginkel T, Lissenberg-Witte BI, Beckers GMA et al (2018) The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with non-muscle-invasive bladder cancer. BJU Int 122:571\u2013575","journal-title":"BJU Int"},{"key":"3908_CR23","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2018.4657","volume":"319","author":"EM Messing","year":"2018","unstructured":"Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP Jr et al (2018) Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non\u2013muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial. JAMA 319:1880\u20131888","journal-title":"JAMA"},{"key":"3908_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","volume":"28","author":"R Addeo","year":"2010","unstructured":"Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L et al (2010) Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 28:543\u2013548","journal-title":"J Clin Oncol"},{"key":"3908_CR25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.eururo.2009.06.010","volume":"56","author":"A B\u00f6hle","year":"2009","unstructured":"B\u00f6hle A, Leyh H, Frei C, K\u00fchn M, Tschada R, Pottek T et al (2009) Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol 56:495\u2013503","journal-title":"Eur Urol"},{"key":"3908_CR26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.euf.2018.07.023","volume":"4","author":"M Babjuk","year":"2018","unstructured":"Babjuk M, Burger M, Comp\u00e9rat EM, Gontero P, Mostafid HA, Palou J et al (2018) Indication for a single postoperative instillation of chemotherapy in non\u2013muscle-invasive bladder cancer: what factors should be considered? Eur Urol Focus 4:525\u2013528","journal-title":"Eur Urol Focus"},{"key":"3908_CR27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/bju.13599","volume":"119","author":"T Onishi","year":"2017","unstructured":"Onishi T, Sugino Y, Shibahara T, Masui S, Yabana T, Sasaki T (2017) Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer. BJU Int 119:276\u2013282","journal-title":"BJU Int"},{"key":"3908_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi G, Glickman MS, Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective. Nat Rev Urol 11:153\u2013162","journal-title":"Nat Rev Urol"},{"key":"3908_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"A Bohle","year":"2003","unstructured":"Bohle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90\u201395","journal-title":"J Urol"},{"key":"3908_CR30","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","volume":"147","author":"DL Lamm","year":"1992","unstructured":"Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW et al (1992) Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 147:596\u2013600","journal-title":"J Urol"},{"key":"3908_CR31","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1200\/JCO.1988.6.9.1450","volume":"6","author":"HW Herr","year":"1988","unstructured":"Herr HW, Laudone VP, Badalament RA, Oettgen HF, Sogani PC, Freedman BD et al (1988) Bacillus Calmette-Gu\u00e9rin therapy alters the progression of superficial bladder cancer. J Clin Oncol 6:1450\u20131455","journal-title":"J Clin Oncol"},{"key":"3908_CR32","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"R J\u00e4rvinen","year":"2009","unstructured":"J\u00e4rvinen R, Kaasinen E, Sankila A, Rintala E (2009) Long-term efficacy of maintenance bacillus Calmette-Gu\u00e9rin versus maintenance mitomycin c instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20. Eur Urol 56:260\u2013265","journal-title":"Eur Urol"},{"key":"3908_CR33","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S0022-5347(17)40002-4","volume":"143","author":"JA Mart\u00ednez-Pi\u00f1eiro","year":"1990","unstructured":"Mart\u00ednez-Pi\u00f1eiro JA, Jim\u00e9nez Le\u00f3n J, Mart\u00ednez-Pi\u00f1eiro L Jr, Fiter L, Mosteiro JA, Navarro J et al (1990) Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 143:502\u2013506","journal-title":"J Urol"},{"key":"3908_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","volume":"173","author":"TM de Reijke","year":"2005","unstructured":"de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K et al (2005) Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer\u2013Genito-Urinary Group Phase III Trial (30906). J Urol 173:405\u2013409","journal-title":"J Urol"},{"key":"3908_CR35","first-page":"47","volume":"69","author":"CM Pinsky","year":"1985","unstructured":"Pinsky CM, Camacho FJ, Kerr D, Geller NL, Klein FA, Herr HA et al (1985) Intravesical administration of bacillus Calmette-Gu\u00e9rin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Cancer Treat Rep 69:47\u201353","journal-title":"Cancer Treat Rep"},{"key":"3908_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0022-5347(17)46972-2","volume":"134","author":"DL Lamm","year":"1985","unstructured":"Lamm DL (1985) Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 134:40\u201347","journal-title":"J Urol"},{"key":"3908_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001986","author":"MD Shelley","year":"2000","unstructured":"Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M (2000) Intravesical Bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD001986","journal-title":"Cochrane Database Syst Rev"},{"key":"3908_CR38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ijsu.2018.02.045","volume":"52","author":"S Chen","year":"2018","unstructured":"Chen S, Zhang N, Shao J, Wang X (2018) Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized clinical trials. Int J Surg (London, England) 52:248\u2013257","journal-title":"Int J Surg (London, England)"},{"key":"3908_CR39","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G et al (2013) Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 63:462\u2013472","journal-title":"Eur Urol"},{"key":"3908_CR40","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA et al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163:1124\u20131129","journal-title":"J Urol"},{"key":"3908_CR41","doi-asserted-by":"publisher","first-page":"5529-9--9","DOI":"10.1002\/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H","volume":"75","author":"H Akaza","year":"1995","unstructured":"Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K (1995) Bacillus Calmette-Gu\u00e9rin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer 75:5529\u20139--9","journal-title":"Cancer"},{"key":"3908_CR42","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/S0022-5347(05)66333-1","volume":"165","author":"J Palou","year":"2001","unstructured":"Palou J, Laguna P, Mill\u00e1n-Rodr\u00edguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodr\u00edguez J (2001) Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and\/or high grade bladder tumors. J Urol 165:1488\u20131491","journal-title":"J Urol"},{"key":"3908_CR43","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk M, Burger M, Comp\u00e9rat EM, Gontero P, Mostafid AH, Palou J et al (2019) European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)\u20142019 Update. Eur Urol 76:639\u2013657","journal-title":"Eur Urol"},{"key":"3908_CR44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/01.ju.0000162059.64886.1c","volume":"174","author":"RJ Sylvester","year":"2005","unstructured":"Sylvester RJ, van der Meijden APM, Witjes JA, Kurth K (2005) Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 174:82\u201386","journal-title":"J Urol"},{"key":"3908_CR45","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.juro.2010.03.032","volume":"184","author":"DC Chade","year":"2010","unstructured":"Chade DC, Shariat SF, Godoy G, Savage CJ, Cronin AM, Bochner BH et al (2010) Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol 184:74\u201380","journal-title":"J Urol"},{"key":"3908_CR46","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","volume":"44","author":"APM van der Meijden","year":"2003","unstructured":"van der Meijden APM, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV (2003) Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European organisation for research and treatment of cancer genito-urinary group phase III Trial. Eur Urol 44:429\u2013434","journal-title":"Eur Urol"},{"key":"3908_CR47","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0022-5347(06)00264-3","volume":"175","author":"MP Koya","year":"2006","unstructured":"Koya MP, Simon MA, Soloway MS (2006) Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 175:2004\u20132010","journal-title":"J Urol"},{"key":"3908_CR48","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1086\/314064","volume":"31","author":"DL Lamm","year":"2000","unstructured":"Lamm DL (2000) Efficacy and Safety of Bacille Calmette-Gu\u00e9rin immunotherapy in superficial bladder cancer. Clin Infect Dis 31:S86\u2013S90","journal-title":"Clin Infect Dis"},{"key":"3908_CR49","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.urology.2007.07.017","volume":"70","author":"MS Agrawal","year":"2007","unstructured":"Agrawal MS, Agrawal M, Bansal S, Agarwal M, Lavania P, Goyal J (2007) The safety and efficacy of different doses of bacillus Calmette Gu\u00e9rin in superficial bladder transitional cell carcinoma. Urology 70:1075\u20131078","journal-title":"Urology"},{"key":"3908_CR50","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","volume":"66","author":"CA Rentsch","year":"2014","unstructured":"Rentsch CA, Birkh\u00e4user FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C et al (2014) Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol 66:677\u2013688","journal-title":"Eur Urol"},{"key":"3908_CR51","first-page":"484.e195","volume":"34","author":"JA Witjes","year":"2016","unstructured":"Witjes JA, Dalbagni G, Karnes RJ, Shariat S, Joniau S, Palou J et al (2016) The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non\u2013muscle-invasive bladder cancer. Urol Oncol Semin Orig Invest 34:484.e195-.e25","journal-title":"Urol Oncol Semin Orig Invest"},{"key":"3908_CR52","unstructured":"Merck to Construct New Facility in the United States to Expand Manufacturing Capacity for TICE\u00ae BCG - Merck.com. https:\/\/www.merck.com\/news\/merck-to-construct-new-facility-in-the-united-states-to-expand-manufacturing-capacity-for-tice-bcg\/. Accessed 23 Dec 2021"},{"key":"3908_CR53","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrurol.2014.52","volume":"11","author":"H Zargar","year":"2014","unstructured":"Zargar H, Aning J, Ischia J, So A, Black P (2014) Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer. Nat Rev Urol 11:220\u2013230","journal-title":"Nat Rev Urol"},{"key":"3908_CR54","first-page":"119","volume":"1","author":"DL Lamm","year":"1995","unstructured":"Lamm DL, Blumenstein BA, David Crawford E, Crissman JD, Lowe BA, Smith JA et al (1995) Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol Semin Orig Invest 1:119\u2013126","journal-title":"Urol Oncol Semin Orig Invest"},{"key":"3908_CR55","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0022-5347(01)67606-7","volume":"153","author":"PDJ Vegt","year":"1995","unstructured":"Vegt PDJ, Witjes JA, Witjes WPJ, Doesburg WH, Debruyne FMJ, van der Meijden APM et al (1995) Original Articles: bladder cancer: a randomized study of intravesical mitomycin c, bacillus calmette-guerin tice and bacillus calmette-guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol 153:929\u2013933","journal-title":"J Urol"},{"key":"3908_CR56","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","volume":"52","author":"MG Friedrich","year":"2007","unstructured":"Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H (2007) Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 52:1123\u20131129","journal-title":"Eur Urol"},{"key":"3908_CR57","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","volume":"93","author":"JLS Au","year":"2001","unstructured":"Au JLS, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL et al (2001) Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III Trial. J Nat Cancer Inst 93:597\u2013604","journal-title":"J Nat Cancer Inst"},{"key":"3908_CR58","first-page":"CD011935","volume":"1","author":"S Schmidt","year":"2020","unstructured":"Schmidt S, Kunath F, Coles B, Draeger DL, Krabbe L-M, Dersch R et al (2020) Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 1:CD011935-CD","journal-title":"Cochrane Database Syst Rev"},{"key":"3908_CR59","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.eururo.2003.09.014","volume":"45","author":"JA Witjes","year":"2004","unstructured":"Witjes JA, van der Heijden AG, Vriesema JLJ, Peters GJ, Laan A, Schalken JA (2004) Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol 45:182\u2013186","journal-title":"Eur Urol"},{"key":"3908_CR60","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","volume":"741","author":"CL de Sousa","year":"2014","unstructured":"de Sousa CL, Monteiro G (2014) Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur J Pharmacol 741:8\u201316","journal-title":"Eur J Pharmacol"},{"key":"3908_CR61","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.2147\/OTT.S170477","volume":"11","author":"Z Ye","year":"2018","unstructured":"Ye Z, Chen J, Hong Y, Xin W, Yang S, Rao Y (2018) The efficacy and safety of intravesical gemcitabine vs Bacille Calmette-Gu\u00e9rin for adjuvant treatment of non-muscle invasive bladder cancer: a meta-analysis. Onco Targets Ther 11:4641\u20134649","journal-title":"Onco Targets Ther"},{"key":"3908_CR62","first-page":"e664","volume":"185","author":"B Lotfy","year":"2011","unstructured":"Lotfy B, Salem K, Ashraf S, Nashwa N (2011) 1655 intravesical gemcitabine versus bacillus calmette-guerin (BCG) in treatment of non-muscle invasive bladder cancer: short term comparative study. J Urol 185:e664\u2013e665","journal-title":"J Urol"},{"key":"3908_CR63","doi-asserted-by":"publisher","first-page":"7800","DOI":"10.1002\/cam4.3513","volume":"9","author":"JL Lu","year":"2020","unstructured":"Lu JL, Xia QD, Lu YH, Liu Z, Zhou P, Hu HL et al (2020) Efficacy of intravesical therapies on the prevention of recurrence and progression of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis. Cancer Med 9:7800\u20137809","journal-title":"Cancer Med"},{"key":"3908_CR64","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1097\/JU.0000000000000297","volume":"202","author":"MM V","year":"2019","unstructured":"V MM, E GJ, Neal S, D GG, Hugh M, C BP (2019) Emerging immunotherapy options for bacillus calmette-gu\u00e9rin unresponsive nonmuscle invasive bladder cancer. J Urol 202:1111\u20139","journal-title":"J Urol"},{"key":"3908_CR65","first-page":"1635","volume":"31","author":"CPN Dinney","year":"2013","unstructured":"Dinney CPN, Greenberg RE, Steinberg GD (2013) Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Gu\u00e9rin. Urol Oncol Semin Orig Invest 31:1635\u20131642","journal-title":"Urol Oncol Semin Orig Invest"},{"key":"3908_CR66","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","volume":"163","author":"G Steinberg","year":"2000","unstructured":"Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M (2000) Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 163:761\u20137","journal-title":"J Urol"},{"key":"3908_CR67","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fonc.2019.00121","volume":"9","author":"D Huang","year":"2019","unstructured":"Huang D, Jin Y-H, Weng H, Huang Q, Zeng X-T, Wang X-H (2019) Combination of Intravesical Bacille Calmette-Gu\u00e9rin and chemotherapy vs Bacille Calmette-Gu\u00e9rin alone in non-muscle invasive bladder cancer: a meta-analysis. Front Oncol 9:121","journal-title":"Front Oncol"},{"key":"3908_CR68","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/j.1464-410X.2012.11390.x","volume":"111","author":"BB Houghton","year":"2013","unstructured":"Houghton BB, Chalasani V, Hayne D, Grimison P, Brown CSB, Patel MI et al (2013) Intravesical chemotherapy plus bacille Calmette-Gu\u00e9rin in non-muscle invasive bladder cancer: a systematic review with meta-analysis. BJU Int 111:977\u2013983","journal-title":"BJU Int"},{"key":"3908_CR69","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12885-015-1431-6","volume":"15","author":"D Hayne","year":"2015","unstructured":"Hayne D, Stockler M, McCombie SP, Chalasani V, Long A, Martin A et al (2015) BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301). BMC Cancer 15:432","journal-title":"BMC Cancer"},{"key":"3908_CR70","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/JU.0000000000000688","volume":"203","author":"RL Steinberg","year":"2020","unstructured":"Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T et al (2020) Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol 203:902\u2013909","journal-title":"J Urol"},{"key":"3908_CR71","first-page":"901","volume":"38","author":"R Babajide","year":"2020","unstructured":"Babajide R, Labbate C, Saoud R, Agarwal PK (2020) Early experience with intravesical gemcitabine-docetaxel for BCG-na\u00efve patients with high grade non-muscle invasive bladder cancer. Urol Oncol Semin Orig Invest 38:901","journal-title":"Urol Oncol Semin Orig Invest"},{"key":"3908_CR72","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1097\/01.ju.0000146274.85012.e1","volume":"173","author":"AG van der Heijden","year":"2005","unstructured":"van der Heijden AG, Verhaegh G, Jansen CFJ, Schalken JA, Witjes JA (2005) Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol 173:1375\u20131380","journal-title":"J Urol"},{"key":"3908_CR73","first-page":"4912","volume":"59","author":"SM Di Stasi","year":"1999","unstructured":"Di Stasi SM, Giannantoni A, Massoud R, Dolci S, Navarra P, Vespasiani G et al (1999) Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res 59:4912\u20134918","journal-title":"Cancer Res"},{"key":"3908_CR74","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-3-319-40389-2_6","volume":"170","author":"MF Dietrich","year":"2016","unstructured":"Dietrich MF, Gerber DE (2016) Chemotherapy for advanced non-small cell lung cancer. Cancer Treat Res 170:119\u2013149","journal-title":"Cancer Treat Res"},{"key":"3908_CR75","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","volume":"69","author":"TJH Arends","year":"2016","unstructured":"Arends TJH, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F et al (2016) Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin c versus bacillus calmette-gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non\u2013muscle-invasive bladder cancer. Eur Urol 69:1046\u20131052","journal-title":"Eur Urol"},{"key":"3908_CR76","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"WS Tan","year":"2019","unstructured":"Tan WS, Panchal A, Buckley L, Devall AJ, Loubi\u00e8re LS, Pope AM et al (2019) Radiofrequency-induced thermo-chemotherapy effect versus a second course of Bacillus Calmette-Gu\u00e9rin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance bacillus Calmette-Gu\u00e9rin T. Eur Urol 75:63\u201371","journal-title":"Eur Urol"},{"key":"3908_CR77","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S1470-2045(20)30147-9","volume":"21","author":"N Kleinmann","year":"2020","unstructured":"Kleinmann N, Matin SF, Pierorazio PM, Gore JL, Shabsigh A, Hu B et al (2020) Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol 21:776\u2013785","journal-title":"Lancet Oncol"},{"key":"3908_CR78","unstructured":"FDA approves mitomycin for low-grade upper tract urothelial cancer | FDA."},{"key":"3908_CR79","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1158\/2326-6066.CIR-16-0267","volume":"5","author":"M Kates","year":"2017","unstructured":"Kates M, Nirschl T, Sopko NA, Matsui H, Kochel CM, Reis LO et al (2017) Intravesical BCG induces CD4(+) T-Cell expansion in an immune competent model of bladder cancer. Cancer Immunol Res 5:594\u2013603","journal-title":"Cancer Immunol Res"},{"key":"3908_CR80","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumigui\u00e9 M et al (2021) Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 22:919\u2013930","journal-title":"Lancet Oncol"},{"key":"3908_CR81","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2019.37.7_suppl.350","volume":"37","author":"AV Balar","year":"2019","unstructured":"Balar AV, Kulkarni GS, Uchio EM, Boormans J, Mourey L, Krieger LEM et al (2019) Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-gu\u00e9rin (BCG). J Clin Oncol 37:350","journal-title":"J Clin Oncol"},{"key":"3908_CR82","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1200\/JCO.2019.37.7_suppl.406","volume":"37","author":"VK Woodcock","year":"2019","unstructured":"Woodcock VK, Purshouse K, Butcher C, Haddon C, Verrall G, Elhussein L et al (2019) A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC). J Clin Oncol 37:406","journal-title":"J Clin Oncol"},{"key":"3908_CR83","unstructured":"Merck Announces Plans to Construct New Facility in the United States to Expand Manufacturing Capacity for TICE\u00ae BCG - Merck.com."},{"key":"3908_CR84","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.20.01665","volume":"39","author":"JWF Catto","year":"2020","unstructured":"Catto JWF, Gordon K, Collinson M, Poad H, Twiddy M, Johnson M et al (2020) Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study. J Clin Oncol 39:202\u2013214","journal-title":"J Clin Oncol"},{"key":"3908_CR85","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1158\/0008-5472.CAN-18-0173","volume":"78","author":"R Saito","year":"2018","unstructured":"Saito R, Smith CC, Utsumi T, Bixby LM, Kardos J, Wobker SE et al (2018) Molecular subtype-specific immunocompetent models of high-grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy. Can Res 78:3954\u20133968","journal-title":"Can Res"},{"key":"3908_CR86","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","volume":"35","author":"ND Shore","year":"2017","unstructured":"Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM et al (2017) Intravesical rAd\u2013IFN\u03b1\/Syn3 for patients with high-grade, bacillus calmette-guerin\u2013refractory or relapsed non\u2013muscle-invasive bladder cancer: a phase ii randomized study. J Clin Oncol 35:3410\u20133416","journal-title":"J Clin Oncol"},{"key":"3908_CR87","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1200\/JCO.2020.38.6_suppl.442","volume":"38","author":"SA Boorjian","year":"2020","unstructured":"Boorjian SA, Dinney CPN (2020) Safety and efficacy of intravesical nadofaragene firadenovec for patients with high-grade, BCG unresponsive nonmuscle invasive bladder cancer (NMIBC): Results from a phase III trial. J Clin Oncol 38:442","journal-title":"J Clin Oncol"},{"key":"3908_CR88","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00345-007-0197-0","volume":"25","author":"AP Mitra","year":"2007","unstructured":"Mitra AP, Birkhahn M, Cote RJ (2007) p53 and retinoblastoma pathways in bladder cancer. World J Urol 25:563\u2013571","journal-title":"World J Urol"},{"key":"3908_CR89","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","volume":"36","author":"VT Packiam","year":"2018","unstructured":"Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL 3rd et al (2018) An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. Urol Oncol 36:440\u2013447","journal-title":"Urol Oncol"},{"key":"3908_CR90","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.juro.2010.09.073","volume":"185","author":"PF Bassi","year":"2011","unstructured":"Bassi PF, Volpe A, D\u2019Agostino D, Palermo G, Renier D, Franchini S et al (2011) Paclitaxel-hyaluronic acid for intravesical therapy of Bacillus Calmette-Gu\u00e9rin refractory carcinoma in situ of the bladder: results of a phase I study. J Urol 185:445\u2013449","journal-title":"J Urol"},{"key":"3908_CR91","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11255-015-0940-1","volume":"47","author":"W Huang","year":"2015","unstructured":"Huang W, Wang F, Wu C, Hu W (2015) Efficacy and safety of pirarubicin combined with hyaluronic acid for non-muscle invasive bladder cancer after transurethral resection: a prospective, randomized study. Int Urol Nephrol 47:631\u2013636","journal-title":"Int Urol Nephrol"},{"key":"3908_CR92","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","volume":"30","author":"J Hedegaard","year":"2016","unstructured":"Hedegaard J, Lamy P, Nordentoft I, Algaba F, H\u00f8yer S, Ulh\u00f8i Benedicte P et al (2016) Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 30:27\u201342","journal-title":"Cancer Cell"},{"key":"3908_CR93","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","volume":"72","author":"EJ Pietzak","year":"2017","unstructured":"Pietzak EJ, Bagrodia A, Cha EK, Drill EN, Iyer G, Isharwal S et al (2017) Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur Urol 72:952\u2013959","journal-title":"Eur Urol"},{"key":"3908_CR94","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.1158\/0008-5472.CAN-20-0977","volume":"80","author":"J Bellmunt","year":"2020","unstructured":"Bellmunt J, Kim J, Reardon B, Perera-Bel J, Orsola A, Rodriguez-Vida A et al (2020) Genomic predictors of good outcome, recurrence, or progression in high-grade T1 non\u2013muscle-invasive bladder cancer. Cancer Res 80:4476","journal-title":"Cancer Res"},{"key":"3908_CR95","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K et al (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21:1353\u20131365","journal-title":"Lancet Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03908-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-021-03908-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03908-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T11:58:22Z","timestamp":1676116702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-021-03908-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":95,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["3908"],"URL":"https:\/\/doi.org\/10.1007\/s00345-021-03908-x","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"13 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A Weickhardt: research funding: MSD, Pfizer, Novartis, and BMS. Travel funding: MSD. Honoraria: MSD and BMS. Advisory board: MSD, BMS, and Merck. M Perera Marlon Perera is sponsored by the Australian-America Fulbright Commission administered through a 2021\u20132022 Fulbright Future Scholarship funded by The Kinghorn Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}